Research Projects

Initial Research Foci 1: HIV-Resistant Anti-HIV CAR T Cells

IRF1 Leaders & Industry Partners:
Lawrence Corey, MD, Fred Hutchinson Cancer Research Center • Seattle, Washington
David Rawlings, MD, Seattle Children’s Hospital • Seattle, Washington
Thor Wagner, MD, Seattle Children’s Hospital • Seattle, Washington
Juno Therapeutics, Seattle, Washington
Gilead Sciences, Foster City, California
Sangamo BioSciences, Richmond, California

 

Initial Research Foci 2: eCD4-Ig based Therapy for HIV Cure

IRF2 Leaders & Industry Partners:
Michael Farzan, PhD, The Scripps Research Institute Florida • Jupiter, Florida
Emmune, Inc., Jupiter, Florida
Gilead Sciences, Foster City, California

 

Initial Research Foci 3: Genetic Protection of T Cells after Therapeutic Vaccination

IRF3 Leaders & Industry Partners:
James Mullins, PhD
, University of Washington • Seattle, Washington
Deborah Fuller, PhD, University of Washington • Seattle, Washington
Hans-Peter Kiem, MD, PhD, Fred Hutchinson Cancer Research Center • Seattle, Washington
Sangamo BioSciences, Richmond, California
Gilead Sciences, Foster City, California